TY  - JOUR
AU  - Schmitz, Sebastian B M
AU  - Gülden, Jakob
AU  - Niederreiter, Marlene
AU  - Eichner, Cassandra
AU  - Werner, Jens
AU  - Mayer, Barbara
TI  - Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib.
JO  - Cells
VL  - 14
IS  - 11
SN  - 2073-4409
CY  - Basel
PB  - MDPI
M1  - DKFZ-2025-01203
SP  - 836
PY  - 2025
AB  - The prognosis of advanced (UICC IIb-IV) primary colorectal cancer (pCRC) remains poor. More effective targeted therapies are needed. Heat shock protein 90 alpha/beta (Hsp90α/β) expression was immunohistologically quantified in 89 pCRCs and multivariately correlated with survival. Pimitespib (Pim, TAS-116), a Hsp90α/β-specific inhibitor, was tested in pCRC cell lines and patient-derived cancer spheroids (PDCS) and referenced to the pan-Hsp90 inhibitor ganetespib (Gan, STA-9090) and standard-of-care therapies. A total of 26.97
KW  - Humans
KW  - HSP90 Heat-Shock Proteins: metabolism
KW  - HSP90 Heat-Shock Proteins: antagonists & inhibitors
KW  - Colorectal Neoplasms: drug therapy
KW  - Colorectal Neoplasms: metabolism
KW  - Colorectal Neoplasms: pathology
KW  - Female
KW  - Male
KW  - Aged
KW  - Middle Aged
KW  - Cell Line, Tumor
KW  - Prognosis
KW  - Triazoles: pharmacology
KW  - Triazoles: therapeutic use
KW  - Spheroids, Cellular: drug effects
KW  - Spheroids, Cellular: metabolism
KW  - CRC (Other)
KW  - Hsp90α/β (Other)
KW  - TAS-116 (Other)
KW  - chemosensitization (Other)
KW  - ganetespib (Other)
KW  - patient stratification (Other)
KW  - patient-derived cancer spheroid model (Other)
KW  - personalized therapy (Other)
KW  - pimitespib (Other)
KW  - prognosis (Other)
KW  - HSP90 Heat-Shock Proteins (NLM Chemicals)
KW  - STA 9090 (NLM Chemicals)
KW  - Triazoles (NLM Chemicals)
KW  - HSP90AB1 protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40498011
C2  - pmc:PMC12154481
DO  - DOI:10.3390/cells14110836
UR  - https://inrepo02.dkfz.de/record/302004
ER  -